Recent 8-K filings for DMAA

• May 5, 2026, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 9.01 ◈ Material Agreements ×3

  DMAA SPAC signs $1B deal to merge with AI/analytics firm Power Analytics Global

  Definitive merger agreement with Power Analytics Global (PAGC) at target enterprise value of $1.0B; floor of $300M.

• May 1, 2026, 7:59 PM ET other material materiality 0.85 neutral item 5.03item 5.07item 8.01item 9.01 ◈ Governance Changes◈ Shareholder Votes

  SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M

  Extension proposal approved: 18,906,281 for, 4,892,646 against, 0 abstain.

• April 28, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  DMAA updates CFO equity to 175k shares, sets CEO compensation terms, both tied to definitive deal

  CFO Saleem Elmasri's share grant increased from 100k to 175k ordinary shares, earned upon signing a definitive agreement and issued at closing of initial business combination.

• April 8, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 8.01item 9.01

  DMAA signs LOI for de-SPAC merger with Power Analytics Global Corp at ~$1B valuation

  Non-binding letter of intent signed April 7, 2026, with target Power Analytics Global Corp (Delaware).

• March 27, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 8.01item 2.03item 9.01 ◈ Material Agreements ×2◈ Debt Financings

  DMAA SPAC enters $100K convertible bridge as first step of $500K financing; identifies AI/cybersecurity target

  BV Advisory Partners provides $100K convertible note (up to $500K total) for compliance and transaction expenses.

• March 6, 2026, 6:59 PM ET leadership materiality 0.70 negative item 5.02

  CEO Lynn Stockwell resigns after affiliate fund irregularities; Roger Bendelac appointed CEO

  Lynn Stockwell resigned as CEO, Executive Chair, and Board member of DMAA and affiliate, effective Feb 28, 2026.

• March 6, 2026, 6:59 PM ET other material materiality 0.50 negative item 8.01

  Drugs Made In America confirms trust account intact after affiliate irregularities

  Sponsor made improper withdrawals from affiliate's working capital account between Sept 26, 2025 and Dec 31, 2025.

• November 18, 2025, 6:59 PM ET leadership materiality 0.40 neutral item 5.02

  CFO Glenn Worman resigns; Saleem Elmasri appointed as CFO of Drugs Made In America Acquisition Corp.

  Glenn Worman resigned as CFO and principal financial & accounting officer on Oct 8, 2025; no disagreement cited.

• February 25, 2025, 6:59 PM ET other material materiality 0.30 neutral item 3.02item 8.01item 9.01

  SPAC raises $30M via over-allotment; trust now $231.15M

  Underwriters exercised over-allotment option in full on Feb 18, 2025; 3M additional units at $10/unit raised $30M.

• February 24, 2025, 6:59 PM ET other materiality 0.20 neutral item 8.01item 9.01

  Drugs Made In America Acquisition Corp. announces separate trading of shares and rights starting Feb 25

  Effective Feb 25, 2025, holders of units (DMAAU) may separate into ordinary shares (DMAA) and rights (DMAAR).

• February 4, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Drugs Made In America Acquisition Corp. closes $200M IPO and $4M private placement

  IPO of 20,000,000 units at $10.00 each raises $200,000,000 gross proceeds.

• January 30, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 5.03item 8.01item 9.01 ◈ Governance Changes

  Drugs Made In America Acquisition Corp. closes $200M IPO, deposits $201M in trust

  Closed IPO of 20,000,000 units at $10.00 per unit for gross proceeds of $200 million.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.57 · Most common event other_material

1 positive 2 negative 9 neutral

source · DMAA on sec.gov